Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 05:01 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer
NCT03579472 · M.D. Anderson Cancer Center · PHASE1 · terminated · last registry update 2022-10-31 · Breast cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Due to the fact that the sponsor decided not to move forward with the development of M7824” | Open Targets' class: business administrative | Registry record, M.D. Anderson Cancer Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CD274 in breast cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-10-27Phase 3 first posted: AstraZeneca, Dato-DXd + Durvalumab (NCT06103864)
- 2023-09-28Phase 3 first posted: National Cancer Institute (NCI), Cyclophosphamide + Doxorubicin (NCT06058377)
- 2023-03-21Results posted on the registry: City of Hope Medical Center, Atezolizumab + Capecitabine (NCT03853707)
- 2022-11-29Phase 3 first posted: AstraZeneca, Dato-DXd + Durvalumab (NCT05629585)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision